The potential predictive role of TMB in mCRC was also investigated in a subgroup of MSS CRC patients associated with O6-Methylguanine-DNA-methyltransferase (MGMT)-deficiency, showing as using temozolomide led to the appearance of neo mutations and tumor neoantigens, prompting to immunotherapy effectiveness [86,87]. Here, MGMT is linked to neoplasm.